Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869753 | 1.00 | BLM (0.58) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL997621 | 1.00 | BLM (0.58) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL1781111 | 0.95 | BLM (0.52) | BLMLMNACA1PTPN1ALDH1A1 | |
| SCHEMBL12153331 | 0.86 | CA1 (0.48) | BLMCA1ALDH1A1TDP1KISS1R | |
| SCHEMBL1784505 | 0.83 | BLM (0.44) | BLMCA1ALDH1A1TDP1KISS1R | |
| SCHEMBL12153332 | 0.83 | CA1 (0.46) | BLMCA1LTA4H | |
| SCHEMBL13410354 | 0.80 | GABRR1 (0.46) | BLMCA1ALDH1A1TDP1LTA4H | |
| SCHEMBL12410220 | 0.79 | — | — | |
| SCHEMBL7546267 | 0.79 | — | — | |
| SCHEMBL20489993 | 0.79 | BLM (0.58) | BLMLMNACA1PTPN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20130137667-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | Board of Regents, Univesity of Texas System (US) | 2013-05-30 | — | — | US | disclosed |
| US-20110028443-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2011-02-03 | — | — | US | disclosed |
| US-7825269-B2 | Ligands for nematode nuclear receptors and uses thereof | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070219173-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137667-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | NR4A1, NR0B1, NR1H2 | BLM 3717/4885LMNA 1603/4885CA1 4722/4885 |
| US-20070219173-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | NR1H2, NR4A1, NR0B1 | BLM 3200/4885LMNA 1208/4885CA1 4855/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | BLM 4123/4885LMNA 2135/4885CA1 4847/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | BLM 4123/4885LMNA 2135/4885CA1 4847/4885 |
| US-20110028443-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | NR4A1, NR0B1, NR1H2 | BLM 3717/4885LMNA 1603/4885CA1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.